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Summary: This new systematic review and analysis suggests BCG vaccination in infancy or BCG 
vaccination when stringent tuberculin testing excludes those with a small degree of prior infection or 
sensitization to environmental mycobacteria protects against pulmonary diseases even in the tropics 
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Abstract  
Background: Randomized trials assessing BCG vaccine protection against tuberculosis have widely 
varying results, for reasons that are not well understood.  
Methods:  
We examined associations of trial setting and design with BCG efficacy against pulmonary and 
miliary or meningeal tuberculosis by conducting a systematic review, meta-analyses and meta-
regression. 
 Results: 
We identified 18 trials reporting pulmonary and 6 miliary or meningeal tuberculosis. Univariable 
meta-regression indicated efficacy against pulmonary tuberculosis varied according to three 
characteristics. Protection appeared greatest in children stringently tuberculin tested, to try to exclude 
prior infection with M tuberculosis or sensitisation to environmental mycobacteria (rate ratio [RR] 
0.26; 95% CI 0.18-0.37), or infants (0.41; 0.29-0.58). Protection was weaker in children not 
stringently tested (0.59; 0.35-1.01) and older individuals stringently or not-stringently tested (0.88; 
0.59-1.31 and 0.81; 0.55-1.22 respectively).  Protection was higher in trials further from the equator 
where environmental mycobacteria are less and with lower risk of diagnostic detection bias. These 
associations were attenuated in a multivariable model, but each had an independent effect. There was 
no evidence that efficacy was associated with BCG strain. Protection against meningeal and miliary 
tuberculosis was also high in infants (RR 0.1; 95% CI 0.01-0.77) and children stringently tuberculin 
tested (0.08; 0.03-0.25).   
Conclusions:  
Absence of prior M tuberculosis infection or sensitisation with environmental mycobacteria is 
associated with higher fficacy of BCG against pulmonary tuberculosis and possibly against miliary 
and meningeal tuberculosis. Evaluations of new tuberculosis vaccines should account for the 
possibility that prior infection may mask or block their effects.  
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Introduction  
Bacillus Calmette Guérin (BCG) vaccine is included in the childhood vaccination programme of 
many countries. However, varying estimates of its efficacy in preventing pulmonary tuberculosis, the 
major burden of tuberculosis disease, have been found in controlled trials[1;2] ranging from 0% in the 
Chingleput Trial in South India to 80% in the UK Medical Research Council trial[3-5]. Consistently 
high estimates of efficacy have been reported for infant BCG vaccination against severe primary 
progressive disease[6;7;8] .  
 
Previous systematic reviews noted a  positive association between BCG vaccine efficacy against 
pulmonary disease with distance from the equator at which studies were conducted[2;9], possibly 
related to exposure to environmental mycobacteria, which is in general, less common distant from the 
equator[1]. Consistent with this hypothesis, a recent sub-analysis of the Chingleput Trial suggested 
some protection (efficacy 29%) among participants who had low tuberculin reactivity and no reaction 
to non-tuberculous mycobacterial antigen (Mycobacterium intracellulare) at baseline, [10]. Other 
possible explanations for variability in the efficacy of BCG against pulmonary disease include the role 
of study quality[11] and that different BCG strains induce different levels of protection[12]. 
 
An improved understanding of why BCG vaccine efficacy varies to such a great extent is important to 
inform assessment of the new generation of tuberculosis vaccines undergoing clinical trials[13], most 
of which are designed to boost protection by BCG. We conducted a systematic review of all reported 
BCG trials, in order to estimate the efficacy of BCG against pulmonary, miliary and meningeal 
tuberculosis and examine associations of study characteristics, including immunological naïvity to 
infection, with efficacy.  
 
Methods  
 We searched for studies reporting primary data on BCG vaccination efficacy in preventing 
tuberculosis disease in human populations of any age, in which BCG (without re-vaccination) was 
compared with no vaccination (placebo or other control). We excluded non-BCG tuberculosis 
vaccines (e.g. vole bacillus, Savioli anti-tuberculosis vaccine or other heat-killed bacillus vaccines) 
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and oral BCG. We did not restrict searches by study design, language, publication date or whether 
fully published. Two reviewers independently screened titles and abstracts, resolving disagreement 
via a third reviewer. We retrieved full papers if assessment from the abstract was not possible or if 
one reviewer considered them potentially eligible. This paper is limited to findings from randomized 
or quasi-randomized trials that reported pulmonary, miliary or meningeal tuberculosis outcomes. 
 
We searched 10 medical literature electronic databases from inception to May 2009, and other 
databases including Google Scholar and trial registers to October 2009. An information specialist 
helped combine MeSH and text word terms for disease and intervention into search strategies 
appropriate for the different databases. Search terms included tuberculosis, tubercle bacill*, M. bovis, 
M. africanum, M. canetti, M. microti and M. tuberculosis. Terms for the intervention included BCG 
Vaccine, BCG, bacillus calmette. (See supplementary appendix for sources and search strategy). We 
identified duplicate or multiple publications, and used the most recent available data in analyses. One 
person extracted data onto structured piloted forms, another checked accuracy and completeness. For 
non-English language publications, one person discussed and agreed upon data to be extracted with an 
extractor fluent in the language of publication. Disagreements were resolved through discussions with 
other members of the study team . As most papers were published before 1973, authors were not 
contacted if data were not available. 
 
We extracted trial characteristics, case definitions, outcomes, and summary results. Trial 
characteristics included distance from the equator by degrees of latitude (collapsed into 20o latitude 
groups for analysis) and whether tests for tuberculin sensitivity (a marker of prior M tuberculosis 
infection as well as some indication of sensitisation to other mycobacteria[4]) with purified protein 
derivative (PPD) were conducted and whether a stringent testing protocol was used. Participants 
vaccinated as infants were assumed tuberculin negative. A stringent tuberculin testing protocol  was 
defined as re-testing initially tuberculin negative participants using a higher dose of tuberculin to 
confirm negativity before vaccination. A non-stringent tuberculin testing protocol was defined as one 
that did not exclude non-infant participants based on tuberculin testing prior to vaccination, or which 
excluded subjects based on only a single tuberculin test.      
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BCG strain variation was assessed in terms of attenuation lineage, the molecular basis of which was 
classified by Brosch et al[12].  We classified strains in the three groups proposed.  We also tested an 
hypothesis that as BCG strains evolved over time there would be a loss of protection. 
 
We assessed risk of bias in trial results based on the Cochrane Collaboration’s Risk of Bias tool[14], 
with additional items specific to BCG trials. We did not consider placebo vaccination as blinded 
during follow up as BCG leaves a scar.  In addition, we assessed likelihood of diagnostic detection 
bias specific to the mode of presentation of pulmonary tuberculosis, based on Clemens et al[11] who 
noted a substantial proportion of tuberculosis is missed if disease is identified only using passive 
follow-up. There is thus a potential for bias if assessors were aware of the trial hypothesis and were 
not blinded to presence or absence of a BCG scar. Trials in which follow-up was active with regular 
chest X ray or other assessments were judged as at low likelihood of such bias, whether or not 
assessors were blind, as were trials with passive follow-up in which outcomes were from routine 
surveillance and assessors were blind to BCG status. Trials using other methods of ascertainment 
were judged to have a greater likelihood of diagnostic detection bias.  
 
For each trial, we estimated the rate ratio (RR) of tuberculosis, comparing vaccinated with 
unvaccinated participants, together with the standard error of the log rate ratio. Vaccine efficacy is 
defined as 1-RR.  Pooled results , together with both fixed- and random-effects summary effect 
estimates, were obtained from fixed-effect (inverse variance weighted) and DerSimonian and Laird 
random-effects meta-analyses[15] of (log) rate ratios from each study.  If one of the randomised 
groups in a trial had 0 cases, 0.5 was added to each cell of the 2x2 table.  Results from both types of 
meta-analysis were included in forest plots: differences between them may suggest the presence of 
small study effects[14].  We also examined possible strain effects by plotting estimated rate ratios 
against the year the study started.  
 
Differences in efficacy between sub-groups of studies were quantified using random-effects meta-
regression to estimate ratios of rate ratios.  Heterogeneity between studies was quantified by 
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estimating the between-study variance τ2.  In forest plots and meta-analyses, τ2 was estimated using 
the method-of-moments estimator proposed by DerSimonian and Laird.  For meta-regression 
analyses, τ2 was estimated by restricted maximum-likelihood, using the metareg command in Stata.  
 
Results  
From 21,030 titles and abstracts we identified 847 articles for retrieval.  We included 211 relevant 
papers, (60 not published in English).  These articles reported data on 21 randomised or quasi-
randomised trials (supplementary figure 1), of which 18 reported on pulmonary tuberculosis, and six 
on meningeal and/or miliary tuberculosis outcomes.  Ten trials were conducted in the USA between 
1933 and 1950[16-25]; four in India between 1950 and 1988[26-29]; one each in Canada (started in 
1933) [30], the UK (1950)[31], South Africa (1965)[32] and Haiti (1965) [33] (Table 1). 
Supplementary table 1 provides further details  of each trial. 
 
Protection against pulmonary tuberculosis 
The efficacy of BCG against pulmonary tuberculosis ranged from substantial protection, in the UK 
MRC trial[31] (RR 0.22; 95% CI 0.16-0.31), to absence of clinically important benefit, in the 
Chingleput trial[28] (1.05; 0.88-1.25)). Figure 1 shows the ratio of the rates of pulmonary tuberculosis 
among BCG vaccinated and controls in each trial, stratified according to age at vaccination and 
stringency of pre-vaccination tuberculin testing, with fixed- and random-effects summary effects 
estimates overall and within strata, and estimates of between-trial heterogeneity. There was less 
heterogeneity within strata (all estimates of τ2 less than 0.095) than overall (τ2=0.38). The average 
protection by BCG was greatest in trials of school-age vaccination with stringent tuberculin testing 
prior to vaccination (random-effects RR 0.26; 95% CI 0.18-0.37) and studies of neonatal vaccination 
(0.41; 0.29-0.58). Fixed- and random-effects estimates were similar within strata and overall. There 
was no consistent evidence of protection in trials including participants older than school age although 
some protection was found in adults in some trials.  
 
Consistent with previous observations, there were marked differences in estimated efficacy according 
to latitude at which trials were conducted. The protective effect of BCG was on average greater in 
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trials conducted at latitudes furthest from the equator.  Although estimated between-trial heterogeneity 
was lower within latitude strata than overall, there was evidence of heterogeneity between trials at 
more than 40° latitude (τ2=0.12, figure 2).  Protection was in general absent or low in trials closer to 
the equator (latitudes <20° and 20°-40°).  Among trials in which outcome assessors were considered 
adequately blinded to participants’ vaccination status , or if there was active surveillance, there was 
substantial between-study variation but the average protective effect of BCG against pulmonary 
tuberculosis was greater (random-effects RR 0.40; 95% CI 0.25-0.64) than in trials with higher 
likelihood of diagnostic detection bias (0.78; 0.64-0.95) (Figure 3).  
 
When trials were stratified according to BCG strain lineage, there was substantial between-trial 
heterogeneity within each stratum, while the average effect of BCG vaccination was similar for each 
strain group (supplementary figure 2, Figure 3). There was no clear relationship between estimated 
vaccine efficacy and year the trial was started, either overall or within strain group (figure 4).  
 
Univariable meta-regression analyses suggested that, among the trial characteristics considered,  
distance from the equator and age at vaccination/tuberculin testing stringency explained the majority 
of between-trial variation in the effect of BCG (residual τ2 0.086 and 0.044 respectively, compared to 
0.284 estimated using a meta-regression model without study characteristics) (Table 2).  Average 
protection was lower in trials conducted at 0o-20o and 20o-40o latitude, compared with those 
conducted at >40o latitude   There was also good evidence that protection was lower in trials including 
participants older than school age than in studies of neonatal vaccination.  There was some evidence 
that average protection was lower in studies with higher likelihood of diagnostic detection bias 
compared with studies with lower likelihood of such bias, although this characteristic explained only 
18% of the between-trial heterogeneity. There was little evidence that protection varied according to 
other study design characteristics, or BCG strain. 
 
Because latitude has previously been associated with protection by BCG, we next fitted two-variable 
meta-regression models including latitude and each other characteristic. These analyses indicated that 
latitude and age at vaccination/tuberculin testing stringency could explain all of the between-trial 
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heterogeneity (residual τ2=0). The final multivariable regression model, which also explained the 
between-trial heterogeneity, included the variables latitude, age at vaccination/tuberculin testing 
stringency, and likelihood of diagnostic detection bias.  Estimated ratios of rate ratios were attenuated 
compared with univariable analyses, but each of these characteristics was separately associated with 
the effect of BCG, having accounted for the other two.  
  
Protection against meningeal or miliary tuberculosis 
The six trials that reported on meningeal and miliary tuberculosis found substantial protection by 
BCG (RR 0.15; 95% CI 0.08, 0.31) with little evidence of between-trial heterogeneity (p=0.14, figure 
5). Protection appeared greatest in the two trials of neonatal vaccination (0.10; 0.01, 0.77), and the 
two trials of school age vaccination with stringent tuberculin testing (0.08; 0.03; 0.25). The two trials 
with non-stringent tuberculin testing (one at school age and one at a range of ages) found little 
evidence of protection. However, ratios of rate ratios were imprecisely estimated in meta-regression 
analyses (supplementary table 2 ), and there was no strong evidence that the efficacy of BCG varied 
according to this or other trial characteristics. 
 
Discussion  
We found three study characteristics to be associated with estimated protection by BCG against 
pulmonary tuberculosis. As well as the well-known association of protection with increasing latitude 
at which trials were conducted, our analysis indicates that protection was greater when BCG was 
given in infancy or at school age, in trials that used stringent tuberculin testing to try to exclude 
participants already sensitised to mycobacteria, and in studies with lower likelihood of diagnostic 
detection bias. Together, these factors were sufficient to explain the between-study variation in the 
protective effect BCG against pulmonary tuberculosis. We found little evidence that other study 
characteristics or BCG vaccine strain were associated with protection. Protection against meningeal 
and miliary tuberculosis also appeared greater than for pulmonary tuberculosis and when BCG was 
given to infants or at school age after stringent tuberculin testing.  
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Randomized controlled trials provide the best evidence for the effectiveness of interventions, but 
many BCG trials were conducted before standard methods for trial conduct and reporting were 
developed. Many used alternation or other “quasi-randomized” methods of allocation to BCG or 
control, which do not guarantee concealment of allocation at recruitment or blinding of participants 
and trial personnel, and some aspects of trial design were not clearly reported.  Previous systematic 
reviews e.g. [9] of 13 trials reporting TB disease outcomes did not assess whether several of these 
design characteristics or the exclusion of those with prior infection or sensitisation to environmental 
mycobacteria using stringent tuberculin testing, were related to BCG protection.  Based on 
comprehensive searches we included the same 13 trials, and found five more eligible trials. We used 
recently developed approaches to assessing risk of bias in trial results. We also assessed additional 
potential biases specific to BCG vaccine trials defined a-priori based on a criterion proposed by 
Clemens et al[11] (blinding of study staff who assessed outcome on BCG status or active 
surveillance) as well as the variability between trials in stringency of pre-vaccination tuberculin 
testing.  We used meta-regression to examine these different possible explanations for variation in the 
estimated effect of BCG across studies.  However, meta-regression analyses have limitations[34]. 
They are ecological analyses with trials as units of observation, hence observed associations may 
result from confounding by other study design characteristics. Studies examined efficacy over varying 
follow-up times. An alternative of restricting to the same period would have reduced the number of 
studies that could be included. Our multivariable analyses included seven variables, which is large 
compared with the total number of studies (18). Therefore, our finding that three characteristics could 
explain all the between-trial variation in the effect of BCG on pulmonary tuberculosis should be 
interpreted with caution. Too few trials reported on miliary and meningeal tuberculosis to allow a 
comprehensive analysis of between-trial heterogeneity.  
 
The effect of latitude on efficacy persisted after adjustment, perhaps because even stringent tuberculin 
testing does not exclude all sensitisation to environmental mycobacteria.  Other proposed explanations 
include human genetic differences, genotypic differences between infecting mycobacteria, or a variety 
of proposed explanations for the association of protection with latitude: exposure to ultraviolet light 
(due to its mycobacterial killing effect); levels of vitamin D, helminthic infestation or the effect of 
 at Library on D
ecem
ber 23, 2013
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
10 
poor nutrition on immune response. Previous reviews concluded that these factors are less plausible 
explanations than exposure to environmental mycobacteria[35].  
 
Previous systematic reviews found substantial variation between trials in estimated protection by 
BCG against pulmonary tuberculosis[2;9], and one estimated average protective efficacy to be 
50%[9].  However, in the absence of explanations for heterogeneity such an average cannot be applied 
to the use of BCG in a particular setting or population. 
 
It is well known there are genetic differences between BCG vaccines, e.g. based on restriction 
fragment length polymorphism typing that suggest BCG strains have undergone evolution since 
1921[12].  Brosch et al. recently used genome sequencing to postulate that BCG vaccines derived 
before 1930 or 1940 may be immunologically superior to more recent and widely used variants [12].  
We found little evidence of an association between estimated effects of BCG with the year each trial 
commenced or that effects varied according to the groups proposed, which include strains currently in 
use: Denmark (in DU2 Group III), Russia (in DU2 Group I) and Japan (also in DU2 Group I) [12].  
Our findings are consistent with results from the UK MRC trial [31], which found equivalent 
protection by the Copenhagen strain of BCG and an M. microti derived vaccine (vole bacillus)[5] 
 
A possible explanation for the low protection observed in trials in southern USA versus high 
protection in the UK was first proposed during the 1960s, based on guinea-pig studies[1]. The 
findings suggested exposure to certain non-tuberculous mycobacterial antigens could mask the 
observed effectiveness of BCG, by providing some protection against tuberculosis in non–vaccinated 
groups, which was not nhanced by BCG vaccination. The authors also noted that populations in 
southern USA, where the trials were carried out, have a high prevalence of sensitivity to M. 
intracellulare and other environmental mycobacteria. The hypothesis that exposure to environmental 
mycobacteria before or after BCG induces an immune response similar to that induced by BCG, so 
that BCG can add little, has been supported by animal and human population studies [2;36]. More 
recent immunogenicity studies suggest exposure to non-tuberculous mycobacterial antigens could also 
block BCG vaccination offering protection when infection precedes vaccination[37]. Our findings are 
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consistent with these hypotheses: perhaps more consistent with the latter, BCG being more effective 
in immunologically naive individuals.  
 
Because of the evidence that BCG protects against miliary and meningeal tuberculosis, in developing 
countries BCG vaccination is recommended at birth (or first contact with health services), taking into 
account HIV status [38].  Our systematic review suggests that BCG also confers protection against 
pulmonary disease, the greatest burden from tuberculosis, when administered both in infancy and at 
school age, providing that children are not already infected with M tuberculosis or sensitised to other 
mycobacterial infections. Protection against pulmonary disease was  seen in the Bombay Infants trial 
suggesting that, even close to the equator, if BCG is administered prior to exposure to tuberculosis 
and environmental mycobacteria it can provide significant protection [27].  Further evidence of 
protection in populations close to the equator from BCG given before infection would strengthen 
these findings. These possible explanations for the observed variation in protection from BCG vaccine 
have implications for the evaluation of new tuberculosis vaccines[39].  If given in conjunction with 
BCG, new vaccines must be shown to offer additional protection against pulmonary disease.  New 
“BCG-like” vaccines may only give protection if administered prior to exposure to M 
tuberculosis[40]. 
 
Funding 
This work was supported by the UK National Institute for Health Research Evaluation, Trials and 
Studies Coordinating Centre (NETSCC,  http://www.netscc.ac.uk/about/.)  [grant number: 08/16/01].  
 
Acknowledgements  
We thank Margaret Burke, who designed and conducted searches of bibliographic databases, and staff 
and students at the London School of Hygiene and Tropical Medicine, the Health Protection Agency 
and Bristol University for translating non-English language papers. We also wish to thank John 
Watson and David Elliman for useful discussions and comments.   
 
 
 at Library on D
ecem
ber 23, 2013
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
12 
Conflict of Interest  
All authors report no conflicts of interests.  
 
References  
 
 1. Palmer CE, Long MW. Effects of infection with atypical mycobacteria on BCG vaccination and 
tuberculosis. Am Rev Respir Dis 1966 Oct;94(4):553-68. 
 2. Fine PEM. Variation in protection by BCG: Implications of and for heterologous immunity. 
Lancet 1995;346(8986):1339-45. 
 3. [No authors listed]. Trial of BCG vaccines in south India for tuberculosis prevention: First 
report 144. Bulletin of the World Health Organization 1979;57(5):819-27. 
 
 4. Fine PE. BCG vaccination against tuberculosis and leprosy. Br Med Bull 1988 Jul;44(3):691-
703. 
 5. Hart PD, Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in 
adolescence and early adult life. Final report to the Medical Research Council. British Medical 
Journal 1977;2(6082):293-5. 
 
 6. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and 
miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 
2006 Apr 8;367(9517):1173-80. 
 7. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous 
meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993 Dec;22(6):1154-8. 
 8. Colditz GA, Berkey CS, Mosteller F, et al. The efficacy of bacillus Calmette-Guerin 
vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the 
published literature. Pediatrics 1995 Jul;96(1 Pt 1):29-35. 
 at Library on D
ecem
ber 23, 2013
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
13 
 9. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of 
tuberculosis. Meta-analysis of the published literature. JAMA 1994 Mar 2;271(9):698-702. 
 10. Tuberculosis Research Centre (ICMR). Influence of sex, age & nontuberculous infection at 
intake on the efficacy of BCG: re-analysis of 15-year data from a double-blind randomized 
control trial in South India. 123 ed.  2006. p. 119-24. 
 
 11. Clemens JD, Chuong JJ, Feinstein AR. The BCG controversy. A methodological and statistical 
reappraisal. JAMA 1983 May 6;249(17):2362-9. 
 12. Brosch R, Gordon SV, Garnier T, et al. Genome plasticity of BCG and impact on vaccine 
efficacy. Proc Natl Acad Sci U S A 2007 Mar 27;104(13):5596-601. 
 13. Dye C, Fine PE. A major event for new tuberculosis vaccines. Lancet 2013 Feb 4. 
 14. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing 
risk of bias in randomised trials. BMJ 2011;343:d5928. 
 15. Dersimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986 Sep;7(3):177-
88. 
 16. Rosenthal SR. BCG Vaccination in All Age Groups. Methods and Results of a Strictly 
Controlled Study. Journal of the American Medical Association 1948;136(2):73-9. 
 
 17. Aronson JD. Protective vaccination against tuberculosis with special reference to BCG 
vaccination. American review of tuberculosis 1948;58(3):255-81. 
 18. Rosenthal SR. Tuber-culin Reaction Trends and BCG Vaccination. Special reference to Young 
Adults (Medical Students) Arch Envir Hlth 1926;11(6):794-803. 
 
 19. Rosenthal SR, Afremow ML, Nikurs L, et al. BCG vaccination and tuberculosis in students of 
nursing.The American Journal of Nursing 1963;63(6):88-93. 
 at Library on D
ecem
ber 23, 2013
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
14 
 
 20. Rosenthal SR, Blahd M, Leslif EI. Ten years' experience with BCG (experimental and clinical) 
The Journal of Pediatrics 1945;26(5):470-80. 
 
 21. Shaw LW. Field studies on immunization against tuberculosis. I. Tuberculin allergy following 
BCG vaccination of school children in Muscogee County, Georgia. Public Health Reports 
1951;66(44):1415-49. 
 22. Bettag OL, Kaluzny AA, Morse D, Radner DB. BCG study at a state school for mentally 
retarded. Chest 1964;45(5):503-7. 
 23. Levine MI. Immunization against Tuberculosis. A Study of the Essential Factors.  American 
Review of Tuberculosis and Pulmonary Diseases 1938;1938. 38:632-43. 
 
 24. Palmer CE. Community Trials of BGG Vaccination. American Review of Tuberculosis and 
Pulmonary Diseases 1958;77:6-907. 
 
 25. Aronson NE. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 
60-year follow-up study.  JAMA 2004; 291:17-2091. 
 
 26. Mehrotra AK, Dabral SB, Nandan D, et al. Assessment of efficacy of BCG vaccination among 
slum children of Agra city. Indian Journal of Public Health 1988;32(3). 
 27. Mehta KP, Merchant SM, Korde U. Environmental influence on immunity due to B.C.G. 
vaccination. Indian Pediatrics 1976;13(7):525-32. 
 
 28. Baily GVJ, Narain R, Mayurnath S. Tuberculosis Prevention Trial, Madras. Indian Journal of 
Medical Research 1980;72(SUPPL.):74p. 
 
 at Library on D
ecem
ber 23, 2013
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
15 
 29. Frimodt-Moller J. A community-wide tuberculosis study in a South Indian rural population, 
1950-1955. Bulletin of the World Health Organization 1960;22:61-170. 
 30. Ferguson RG, Simes AB. BCG vaccination of Indian infants in Saskatchewan. Tubercle 
1949;30(1):5-11. 
 31. [No authors listed]. B.C.G. and vole bacillus vaccines in the prevention of tuberculosis in 
adolescents; first [progress] report to the Medical Research Council by their Tuberculosis 
Vaccines Clinical Trials Committee. British Medical Journal 1956;1(4964):413-27. 
 32. Coetzee AM, Berjak J. B.C.G. in the prevention of tuberculosis in an adult population. 
Proceedings of the Mine Medical Officers" Association 1968;48(402):41-53. 
 
 33. Vandiviere HM, Dworksi M, Melvin IG. Efficacy of bacillus Calmette Guerin and isoniazid 
resistant bacillus Calmette Guerin with and without isoiazid chemoprophylaxis from day of 
vaccination. II. Field trial in man. American Review of Respiratory Disease 1973;108(2):301-
13. 
 
 34. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and 
interpreted? Stat Med 2002;21(11):1559-73. 
 35. Fine PEM, Carneiro IAM, Milstien JB, Clemens JD. Issues relating to the use of BCG in 
immunization programmes. Geneva: WHO; 1999. Report No.: WHO/V&B/99.23. 
 36. Valadas E. Nontuberculous mycobacteria: clinical importance and relevance to bacille 
Calmette-Guerin vaccination. Clin Infect Dis 2004 Aug 15;39(4):457-8. 
 37. Andersen P, Doherty TM. The success and failure of BCG - implications for a novel 
tuberculosis vaccine. Nat Rev Microbiol 2005;3(8):656-62. 
 38. World Health Organization. Revised BCG vaccination guidelines for infants at risk for HIV 
infection. 82 ed.  2007. p. 193. 
 at Library on D
ecem
ber 23, 2013
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
16 
 39. Kaufmann SH, Hussey G, Lambert PH. New vaccines for tuberculosis. Lancet 2010 Jun 
12;375(9731):2110-9. 
 40. Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new 
tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-
controlled phase 2b trial. Lancet 2013 Feb 1. 
 
 
 
 
 
 
 
 
 
 at Library on D
ecem
ber 23, 2013
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
17 
Table 1- Characteristics of included trials of BCG vaccine against pulmonary and miliary or meningeal tuberculosis.  
Trial (First author) Years (start 
of entry to 
end of 
follow-up) 
Number 
BCG 
vaccinated/ 
Number 
unvaccinated 
 Latitude band 
(distance from 
equator)  
Age at vaccination and 
tuberculin testing stringency 
(where applicable) 
Likelihood of 
diagnostic 
detection bias  
Vaccine strain   
Saskatchewan Infants  (Ferguson)[30]* 1933 -1948 306/303  50o+ Neonatal lower Frappier/Pasteur 450-S1, 468-S1  
Native American (Aronson)[25]* 1935-1998 1551/1457  40o-50o School Age, Stringent lower Phipps/Pasteur 317 used at US sites; Pasteur 575 used 
at Alaskan sites 
 
Chicago Infants CCH (Rosenthal)[20]* 1937-1960 5426/4128  40o-50o Neonatal lower Pasteur, Tice  
Turtle and Rosebud Infants (Aronson)[17] 1938-1946 123/139  40o-50o Neonatal lower Phipps,   
Chicago Infants (TT HH) (Rosenthal)[20] 1941 -1953 311/250  40o-50o Neonatal lower Pasteur Tice   
Ida B. Wells Housing Project 
(Rosenthal)[16] 
1942- 1956 699/625  40o-50o School Age, Stringent lower Pasteur, Tice   
US Mental Health Patients (Rosenthal)[16] 1944-1948 20/15  30o-40o Other Age, Stringent higher Pasteur, Tice   
Illinois Mentally Handicapped (Bettag)[22] 1947-1959 531/494  40o-50o Other Age, Stringent higher Not specified  
Georgia (School) (Shaw)[21] 1947-1967 2498/2341  30o-40o School Age, Stringent higher Tice 811K, 811L, 812E, 
812L, 813E  
Puerto Rico Children (Palmer)[24]* 1949-1968 50634/27338  10o-20o School Age, Non Stringent higher Phipps  
Madanapelle (Frimodt-Moller)[29] 1950-1971 5069/5803  10o-20o Other Age, Stringent lower Danish/Copenhagen   
Georgia/Alabama (Palmer)[24]* 1950-1970 16913/17854  30o-40o Other Age, Non Stringent higher Tice   
MRC (MRC)[31]* 1950-1970 20800/13300  50o+ School Age, Stringent lower Danish/Copenhagen  
African Gold Miners (Coetzee)[32] 1965-1968 8317/7997  20o-30 Other Age, Non Stringent lower Glaxo  
Haiti (Vandivière)[33] 1965-1968 641/340  10o-20o Other Age, Non Stringent lower Frappier/Montreal, 1202-  
Chingleput (TBPT)[28] 1968-1983 73459/36404  10o-20o Other Age, Non Stringent lower Danish/Copenhagen/1331, Paris/Pasteur- 1173 P2  
Bombay Infants (Mehta)[27] 1976** 396/300  10o-20o Neonatal lower Danish/Copenhagen  
Agra (Mehrotra)[26] 1988** 1259/1259  20o-30o School Age, Non Stringent lower Not specified  
CCH: County Cook Hospital; MRC: Medical Research Council; TT HH: Tuberculous households 
* Miliary and/or meningeal outcomes reported as well as pulmonary disease outcomes 
** Date of study publication was used if study start date was not available.) 
 
 
 at Library on December 23, 2013 http://cid.oxfordjournals.org/ Downloaded from 
Ac
ce
pte
d M
an
us
cri
pt
18 
Table 2 - Ratios of rate ratios comparing pulmonary tuberculosis among vaccinated and unvaccinated individuals, estimated using meta-regression.  
   Univariable model Two-variable model Multivariable model (τ2 =0) 
 No. of trials 
Rate ratio8 
(95% CI) 
Ratio of rate ratios 
(95% CI) p-value
3 τ2 Ratio of Rate Ratios1 (95% CI) p-value τ
2 Ratio of Rate Ratios2 (95% CI) p-value 
Latitude           
40o+ 8 0.31 (0.21- 0.46) 1.00 (ref)    1.00 (ref)  
20o-40o 5 0.68 (0.41- 1.13) 2.17 (1.14- 4.10)   Included in all models  1.17 (0.58- 2.36)  
0o-20o 5 0.77 (0.52- 1.13) 2.45 (1.42- 4.21) 0.008 0.086    1.73 (0.93 -3.25) 0.0544 
Age at Vaccination / Tuberculin Testing Stringency         
Neonatal  5 0.39 (0.24- 0.64) 1.00 (ref)   1.00 (ref)   1.00 (ref)  
School age / stringent 4 0.26 (0.17- 0.40) 0.66 (0.35- 1.25)   0.74 (0.52- 2.67)   0.76 (0.45- 1.26)  
School age / non stringent 2 0.62 (0.38- 1.01) 1.58 (0.80- 3.13)   1.29 (0.64- 2.61)   0.80 (0.37- 1.72)  
Other age / stringent  3 0.94 (0.51- 1.73) 2.38 (1.09- 5.18)   1.83 (0.85- 3.92)   1.60 (0.82- 3.12)  
Other age / non stringent  4 0.85 (0.58- 1.24) 2.16 (1.17- 3.98) 0.003 0.044 1.90 (0.97- 3.73) 0.0644 0.000 1.75 (0.98- 3.15) 0.0134 
Diagnostic Detection Bias         
Lower risk of bias 13 0.43 (0.30- 0.62) 1.00 (ref)   1.00 (ref)   1.00 (ref)  
Higher risk of bias 5 0.95 (0.50- 1.81) 2.22 (1.10- 4.60) 0.036 0.232 1.71 (0.93- 3.14) 0.0774 0.114 1.60 (1.01- 2.54) 0.0454 
Was the allocation sequence adequately generated?         
Lower risk of bias 1 1.05 (0.35- 3.11) 1.00 (ref)   1.00 (ref)     
Higher risk of bias 17 0.48 (0.34- 0.68) 0.46 (0.15- 1.44) 0.169 0.253 0.64 (0.29- 1.43) 0.2554 0.078   
Was treatment allocation adequately concealed?         
Lower risk of bias 3 0.56 (0.22- 1.41) 1.00 (ref)   1.00 (ref)     
Higher risk of bias 15 0.51 (0.34- 0.75) 0.92 (0.34- 2.49) 0.856 0.303 0.86 (0.40- 1.83) 0.6704 0.091   
Was knowledge of the allocated intervention prevented during the study?        
Lower risk of bias 3 0.45 (0.20- 1.02) 1.00 (ref)   1.00 (ref)     
Higher risk of bias 15 0.53 (0.36- 0.80) 1.19 (0.48- 2.96) 0.691 0.319 1.05 (0.48- 2.05) 0.8674 0.128   
Are reports of the study free from the suggestion of selective outcome reporting? 
Lower risk of bias 17 0.50 (0.34- 0.72) 1.00 (ref)   1.00 (ref)     
Higher risk of bias 1 0.81 (0.23- 2.84) 1.62 (0.44- 5.98) 0.445 0.299 1.09 (0.39- 3.05) 0.8604 0.120   
Was ascertainment of cases complete?          
Lower risk of bias 15 0.51 (0.34- 0.74) 1.00 (ref)   1.00 (ref)     
Higher risk of bias 3 0.59 (0.23- 1.53) 1.17 (0.42- 3.24) 0.756 0.310 0.80 (0.37- 1.74) 0.5514 0.103   
BCG Strain5,6          
DU1-DU2-IV 2 0.51 (0.20- 1.32) 1.00 (ref)   1.00 (ref)     
DU2-III 5 0.59 (0.32- 1.10) 1.15 (0.37 - 3.54)   0.90 (0.48- 1.73)     
DU2-IV 11 0.42 (0.25- 0.73) 0.83 (0.28 - 2.45)   0.96 (0.51- 1.81)     
Other7 2 0.75 (0.25- 2.31) 1.47 (0.34 - 6.28) 0.727 0.379 1.54 (0.55- 4.28) 0.0114 0.089   
CI: confidence interval; ref: reference category, τ2: estimated between-study variance; 1: Adjusted for latitude category; 2:Adjusted for all other variables in the model; 3. : Overall P-value for the model for 
the test of the hypothesis that none of the covariates are associated with the overall BCG efficacy  4. The p-value is for the test of the null hypothesis that there is no association between the covariate and 
the overall BCG efficacy.5. Categories derived from Bronsch et al (2007) [12] 6. Two trials reported results stratified according to strain; 7. Not possible to identify the strain used;.8 estimated effects 
displayed in Fig 2 differ from those here, because of the difference between meta-regression and stratified random-effects meta-analysis 
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Figure legends 
Figure 1.  Rate Ratios for pulmonary tuberculosis, stratified by age vaccinated and stringency of pre-
vaccination tuberculin testing.   
Legend: Trials included in this review, ordered by year of study start with rate ratios (RR) and 95% confidence 
intervals (95% CIs).  The “other” age group includes studies in which older persons were vaccinated as well as 
those in which BCG was given at any age. (CCH: Cook County Hospital; D+L: DerSimonian and Laird method; 
M-H: Mantel-Haenszel method; MRC: Medical Research Council; PY: Person-Years; TB HH: Tuberculosis 
Households; TBPT: Tuberculosis Prevention Trial; *Date of study publication was used if study start date was not 
available).  
Figure 2: Rate ratios (95% CIs) for pulmonary tuberculosis, stratified by latitude of study location.   
Legend: Ordered by year of study start. *Date of study publication was used if study start date was not available. CCH: Cook 
County Hospital; D+L: DerSimonian and Laird method; M-H: Mantel-Haenszel method; MRC: Medical Research Council; 
PY: Person-Years; TB HH: Tuberculosis Households; TBPT: Tuberculosis Prevention Trial.  
Figure 3. Pooled rate ratios for pulmonary tuberculosis, estimated using random-effects meta-analysis, 
according to trial characteristics.   
Legend: Rate ratios (RR) and 95% confidence intervals (95% CIs)  
Figure 4: Scatter plot of estimated rate ratios for pulmonary tuberculosis, according to year of study start 
and BCG strain category 
Legend: (DU1-DU2-IV: Tandem duplication 1 and fourth form of tandem duplication 2; DU2-III: Third form of tandem 
duplication 2; DU2-IV: Fourth form of tandem duplication 2, according to Brosch et al. 53).  The efficacy data for two trials 
(Native American 2 and Chingleput 45), were provided for two different strains of BCG, accounting for two extra sets of 
results in this graph 
Figure 5: Rate ratios (95% CIs) for meningeal and/or miliary tuberculosis, stratified by age at vaccination 
and tuberculin testing stringency.   
Legend: Pooled results from fixed effects meta-analysis only as the numbers of studies were small, ordered by year of study 
start. (CCH: Cook County Hospital; D+L: DerSimonian and Laird method; M-H: Mantel-Haenszel method; MRC: Medical 
Research Council; PY: Person-Years; TB HH: Tuberculosis Households; * the outcome is miliary tuberculosis only). 
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